Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the firm behind them -- so individuals can make better investing decisions.

In addition to following professional firms, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 130,000 members, some of whom demonstrate better investing insight than published analysts.

More top-performing CAPS members are having that bullish feeling about Immucor (NASDAQ:BLUD) lately, enough to upgrade it from the three- and four-star ranks it had held for months to the highest-possible five stars. A total of 457 members have given their opinion on Immucor, with many of them offering analysis and commentary explaining the recent optimism.

As hospitals have tightened capital spending and delayed orders of major purchases, medical device makers such as Intuitive Surgical (NASDAQ:ISRG) and Hansen Medical (NASDAQ:HNSN), as well as implantable device makers like Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT), have been experiencing slower sales. Blood transfusion specialist Immucor -- a manufacturer of automated systems for various types of blood tests -- has also experienced pressure on domestic sales of its Galileo system. But demand for the consumable reagents for such systems remains strong, which is nice because the reagents account for about 90% of Immucor's total revenue.

In its most recent quarter, Immucor beat Wall Street's earnings expectations, with revenue growing 12%. The company also anticipates that fiscal 2009 profit will come in at the high end of, or slightly above, its previous guidance. Even though Immucor signed a five-year renewal agreement with Quest Diagnostics (NYSE:DGX) to be its preferred vendor for reagents and blood-bank automation systems, shares have taken a hit recently, after the Department of Justice began investigating Immucor and competitor Johnson & Johnson (NYSE:JNJ) for possible antitrust violations. Regardless of the possible short-term issues, many CAPS members see great long-term potential in Immucor.                

To see what the very best CAPS analysts are saying now about Immucor -- as well as other winning stocks they are picking -- head on over to CAPS and have a look. The community research and resources in CAPS are totally free, unlike analyst opinions reserved for paying clients.

More Foolishness:

Always looking ahead, the Motley Fool Rule Breakers team has recommended stocks like Hansen Medical and Intuitive Surgical to soundly beat the market. To see what other rule-breaking stocks David Gardner is picking today, take a free 30-day trial.

Fool contributor Dave Mock recently upgraded his TV with some fancy rabbit ears -- bring on the digital TV! He doesn't own shares of any companies mentioned here. Hansen Medical and Intuitive Surgical are Rule Breakers recommendations. Quest Diagnostics is an Inside Value pick. Johnson & Johnson is an Income Investor selection. The Fool's disclosure policy was actually part of the Olympic basketball Dream Team -- you probably just never saw it sitting on the bench.